Hossein Borghaei, DO, MS: As far as PD-L1 testing, I’m pretty sure I know how it is at your center because we have very similar systems. But that’s much simpler testing. That’s immunohistochemistry ...
FDA approved a PD-L1 companion test to identify patients with ovarian, fallopian tube or primary peritoneal cancer who may receive first-line Keytruda. The U.S. Food and Drug Administration (FDA) has ...
Guideline updates discussed Thursday at the 2019 National Comprehensive Cancer Network Annual Conference reflect recent practice-changing clinical trials involving pembrolizumab and chemotherapy. The ...
The Dako PD-L1 IHC 22C3 PharmDx Assay has been approved as a companion diagnostic to identify patients with with locally advanced or metastatic urothelial carcinoma who are cisplatin-ineligible for ...
Data presented by the FDA at the 2017 American Society of Clinical Oncology Annual Meeting identified a need for educating community-based oncology practices on testing for programmed death-ligand 1 ...
NORTHFIELD, Ill.--(BUSINESS WIRE)--The College of American Pathologists (CAP), in collaboration with five other societies, developed a draft evidence-based clinical practice guideline that aims to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results